Literature DB >> 20071328

Osteopontin is cleaved at multiple sites close to its integrin-binding motifs in milk and is a novel substrate for plasmin and cathepsin D.

Brian Christensen1, Lotte Schack, Eva Kläning, Esben S Sørensen.   

Abstract

Osteopontin (OPN) is a highly modified integrin-binding protein present in most tissues and body fluids where it has been implicated in numerous biological processes. A significant regulation of OPN function is mediated through phosphorylation and proteolytic processing. Proteolytic cleavage by thrombin and matrix metalloproteinases close to the integrin-binding Arg-Gly-Asp sequence modulates the function of OPN and its integrin binding properties. In this study, seven N-terminal OPN fragments originating from proteolytic cleavage have been characterized from human milk. Identification of the cleavage sites revealed that all fragments contained the Arg-Gly-Asp(145) sequence and were generated by cleavage of the Leu(151)-Arg(152), Arg(152)-Ser(153), Ser(153)-Lys(154), Lys(154)-Ser(155), Ser(155)-Lys(156), Lys(156)-Lys(157), or Phe(158)-Arg(159) peptide bonds. Six cleavages cannot be ascribed to thrombin or matrix metalloproteinase activity, whereas the cleavage at Arg(152)-Ser(153) matches thrombin specificity for OPN. The principal protease in milk, plasmin, hydrolyzed the same peptide bond as thrombin, but its main cleavage site was identified to be Lys(154)-Ser(155). Another endogenous milk protease, cathepsin D, cleaved the Leu(151)-Arg(152) bond. OPN fragments corresponding to plasmin activity were also identified in urine showing that plasmin cleavage of OPN is not restricted to milk. Plasmin, but not cathepsin D, cleavage of OPN increased cell adhesion mediated by the alpha(V)beta(3)- or alpha(5)beta(1)-integrins. Similar cellular adhesion was mediated by plasmin and thrombin-cleaved OPN showing that plasmin can be a potent regulator of OPN activity. These data show that OPN is highly susceptible to cleavage near its integrin-binding motifs, and the protein is a novel substrate for plasmin and cathepsin D.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20071328      PMCID: PMC2832943          DOI: 10.1074/jbc.M109.075010

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome.

Authors:  Richard A Dean; Christopher M Overall
Journal:  Mol Cell Proteomics       Date:  2007-01-01       Impact factor: 5.911

2.  Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin.

Authors:  Yasuyuki Yokosaki; Kumi Tanaka; Fumiko Higashikawa; Keisuke Yamashita; Akira Eboshida
Journal:  Matrix Biol       Date:  2005-09       Impact factor: 11.583

3.  Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications.

Authors:  Brian Christensen; Mette S Nielsen; Kim F Haselmann; Torben E Petersen; Esben S Sørensen
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

4.  A new mechanism for prolactin processing into 16K PRL by secreted cathepsin D.

Authors:  David Piwnica; Isabelle Fernandez; Nadine Binart; Philippe Touraine; Paul A Kelly; Vincent Goffin
Journal:  Mol Endocrinol       Date:  2006-09-07

Review 5.  Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.

Authors:  Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

6.  An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma.

Authors:  V Takafuji; M Forgues; E Unsworth; P Goldsmith; X W Wang
Journal:  Oncogene       Date:  2007-04-23       Impact factor: 9.867

7.  Post-translational modification and proteolytic processing of urinary osteopontin.

Authors:  Brian Christensen; Torben E Petersen; Esben S Sørensen
Journal:  Biochem J       Date:  2008-04-01       Impact factor: 3.857

Review 8.  Control of osteopontin signaling and function by post-translational phosphorylation and protein folding.

Authors:  Christian C Kazanecki; Dana J Uzwiak; David T Denhardt
Journal:  J Cell Biochem       Date:  2007-11-01       Impact factor: 4.429

9.  Elevated urinary plasmin activity resistant to alpha2-antiplasmin in acute poststreptococcal glomerulonephritis.

Authors:  Takashi Oda; Kikuko Tamura; Nobuyuki Yoshizawa; Tetsuzo Sugisaki; Koichi Matsumoto; Motoshi Hattori; Toshihiro Sawai; Tamehachi Namikoshi; Muneharu Yamada; Yuichi Kikuchi; Shigenobu Suzuki; Soichiro Miura
Journal:  Nephrol Dial Transplant       Date:  2008-01-26       Impact factor: 5.992

10.  Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties.

Authors:  Brian Christensen; Christian C Kazanecki; Torben E Petersen; Susan R Rittling; David T Denhardt; Esben S Sørensen
Journal:  J Biol Chem       Date:  2007-05-11       Impact factor: 5.157

View more
  44 in total

1.  The effect of intracrystalline and surface-bound osteopontin on the degradation and dissolution of calcium oxalate dihydrate crystals in MDCKII cells.

Authors:  Lauren A Thurgood; Esben S Sørensen; Rosemary L Ryall
Journal:  Urol Res       Date:  2011-09-20

Review 2.  Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction.

Authors:  Merry L Lindsey; Rogelio Zamilpa
Journal:  Cardiovasc Ther       Date:  2010-07-14       Impact factor: 3.023

Review 3.  Proteolytic Systems in Milk: Perspectives on the Evolutionary Function within the Mammary Gland and the Infant.

Authors:  David C Dallas; Niamh M Murray; Junai Gan
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-07-16       Impact factor: 2.673

4.  Osteopontin is proteolytically processed by matrix metalloproteinase 9.

Authors:  Merry L Lindsey; Fouad A Zouein; Yuan Tian; Rugmani Padmanabhan Iyer; Lisandra E de Castro Brás
Journal:  Can J Physiol Pharmacol       Date:  2015-03-26       Impact factor: 2.273

Review 5.  Emerging patterns of tyrosine sulfation and O-glycosylation cross-talk and co-localization.

Authors:  Akul Y Mehta; Jamie Heimburg-Molinaro; Richard D Cummings; Christoffer K Goth
Journal:  Curr Opin Struct Biol       Date:  2020-01-09       Impact factor: 6.809

6.  Mechanistic peptidomics: factors that dictate specificity in the formation of endogenous peptides in human milk.

Authors:  Andres Guerrero; David C Dallas; Stephanie Contreras; Sabrina Chee; Evan A Parker; Xin Sun; Lauren Dimapasoc; Daniela Barile; J Bruce German; Carlito B Lebrilla
Journal:  Mol Cell Proteomics       Date:  2014-08-29       Impact factor: 5.911

7.  Post-translational modification of osteopontin: effects on in vitro hydroxyapatite formation and growth.

Authors:  Adele L Boskey; Brian Christensen; Hayat Taleb; Esben S Sørensen
Journal:  Biochem Biophys Res Commun       Date:  2012-02-10       Impact factor: 3.575

8.  Expression profile of the matricellular protein osteopontin in primary open-angle glaucoma and the normal human eye.

Authors:  Uttio Roy Chowdhury; Seung-Youn Jea; Dong-Jin Oh; Douglas J Rhee; Michael P Fautsch
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-16       Impact factor: 4.799

9.  Extensive in vivo human milk peptidomics reveals specific proteolysis yielding protective antimicrobial peptides.

Authors:  David C Dallas; Andres Guerrero; Nora Khaldi; Patricia A Castillo; William F Martin; Jennifer T Smilowitz; Charles L Bevins; Daniela Barile; J Bruce German; Carlito B Lebrilla
Journal:  J Proteome Res       Date:  2013-04-24       Impact factor: 4.466

10.  Tailor made plasmin substrates as potential diagnostic tool to test for mastitis.

Authors:  Floris J Bikker; Gerrit Koop; Naomi B Leusink; Kamran Nazmi; Wendy E Kaman; Henk S Brand; Enno C I Veerman
Journal:  Vet Res Commun       Date:  2014-07-06       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.